AtriCure stock, AtriCure

AtriCure stock: Q3 revenue growth, updated 2026 outlook

Published on 11/16/2026 at 03:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AtriCure stock is in focus after the company reported stronger third-quarter revenue and profitability. Management also updated its full-year 2026 outlook.

Quarterly Results And Guidance

  • Third-quarter revenue reached USD 154.5 million, up 15.0 percent year over year.
  • Net income reached USD 4.1 million and adjusted EBITDA rose to USD 26.8 million.
  • AtriCure set 2026 revenue guidance at approximately USD 606 million to USD 610 million.
AtriCure stock, AtriCure, quarterly results, revenue growth, 2026 guidance, medical devices, Illustration mit AI erstellt.

AtriCure reported stronger third-quarter revenue and profitability on November 3, while updating its full-year 2026 outlook. The company said worldwide revenue reached USD 154.5 million, according to its financial-results release.

Revenue Growth Broadens

Revenue increased 15.0 percent from the third quarter of 2025. U.S. revenue rose 17.1 percent to USD 128.0 million, supported by sales of the cryoSPHERE MAX probe, EnCompass clamp and AtriClip FLEX-Mini and AtriClip PRO-Mini devices.

International revenue increased 5.8 percent to USD 26.4 million, with growth across all franchises. AtriCure said minimally invasive ablation sales declined as physicians continued adopting pulsed-field ablation catheters, highlighting a shift within the cardiac-procedure market.

Profitability Improves

Gross profit reached USD 119.4 million, while gross margin expanded to 77.3 percent. Operating income was USD 4.4 million, compared with USD 0.2 million a year earlier.

Net income was USD 4.1 million, against a net loss of USD 0.3 million in the prior-year quarter. Adjusted EBITDA rose 51 percent to USD 26.8 million, and adjusted earnings per share reached USD 0.18, compared with an adjusted loss of USD 0.01 a year earlier. The adjusted figures are non-GAAP measures defined by the company.

Full-Year Outlook Updated

AtriCure now projects 2026 revenue of approximately USD 606 million to USD 610 million. Management also expects adjusted EBITDA of approximately USD 91 million to USD 94 million, net income per share of USD 0.21 to USD 0.27 and adjusted earnings per share of USD 0.40 to USD 0.46.

The outlook keeps attention on execution across open ablation, appendage management and pain management. The company also cited progress in its BoxX-NoAF clinical trial as a factor supporting its longer-term opportunity in cardiac surgery and post-operative pain management.

Business And Market Position

AtriCure develops medical technologies for atrial fibrillation treatment, left atrial appendage management and post-operative pain management. Its portfolio includes surgical ablation systems, AtriClip devices and probes used in cardiac, thoracic and amputation procedures. The company is headquartered in Mason, Ohio, and serves surgeons in markets around the world.

AtriCure Company Facts

  • Company: AtriCure, Inc.
  • Ticker: ATRC
  • Home exchange: Nasdaq
  • Headquarters: Mason, Ohio, United States
  • Focus: Cardiac surgery and post-operative pain management

The S&P 500 provides the broader U.S. equity-market context for AtriCure stock; see current market coverage.

More news and analyses on AtriCure stock are available here.

Disclaimer...
en | boerse | 70518778 |